JAZZ vs ALNY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
JAZZ · Jazz Pharmaceuticals$234.76 ▲ 3.27%
ALNY · Alnylam Pharmaceuticals$155.94 ▼ 0.46%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- JAZZ +76.3%
- ALNY -64.7%
Head to head
| Metric | JAZZ | ALNY |
|---|---|---|
| Price | $234.76 | $155.94 |
| Change today | ▲ 3.27% | ▼ 0.46% |
| Market cap | $15.07B | $20.89B |
| Return, 3 months | -8.5% | -28.1% |
| Return, year to date | +38.1% | -60.8% |
| Return, 1 year | +79.0% | -64.8% |
| P/E (TTM) | 69.5 | 8.1 |
| P/B | 3.6 | 5.8 |
| P/E percentile vs own 5y | 89th | 80th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +10.4% | +16.7% |
| Net profit growth (YoY) | -292.3% | +640.5% |
| Gross margin | 89.1% | 77.3% |
| Operating margin | 24.0% | 19.5% |
| Net margin | 4.4% | 52.8% |
| Return on equity | 5.1% | 138.1% |
| Analyst target vs. price | +30.5% | +103.5% |
| Analyst buy share | 100% | 76% |
| RSI (14) | 60 | 22 |
| 30-day volatility | 37.8% | 90.9% |
| Max drawdown, 1 year | -21.6% | -67.6% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ALNY is the largest of the group by market value.
- JAZZ has returned the most over the past year.
- ALNY carries the lowest trailing P/E.
- ALNY is growing revenue fastest.
- ALNY keeps the most profit per dollar of sales.
- JAZZ has been the calmest stock over the last 30 days.